Table 1 Frequency, age, and gender distribution of primary spine osseous tumors
From: Epidemiological characteristics of primary spinal osseous tumors in Eastern China
Type of tumor | Number (%) | Male | Female | Male vs female | Age range (years) | Mean ± SD (age) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
No. | %a | No. | %a | No. | %a | Male | Female | Total | |||
Benign tumors | 780 | 64.5 | 409 | 33.8 | 371 | 30.7 | 52.4 vs 47.6% | 9–79 | 33.7 ± 19.2 | 35.9 ± 20.6 | 34.7 ± 19.8 |
Hemangioma | 340 | 28.1 | 174 | 14.4 | 166 | 13.7 | 51.2 vs 48.8% | 12–79 | 47.1 ± 14.3 | 51.5 ± 12.9 | 49.2 ± 13.7 |
Giant cell tumor | 190 | 15.7 | 91 | 7.5 | 99 | 8.2 | 47.9 vs 52.1% | 15–66 | 34.5 ± 11.0 | 32.9 ± 12.1 | 33.6 ± 11.5 |
Eosinophililc granuloma | 47 | 3.9 | 36 | 3.0 | 11 | 0.9 | 76.6 vs 23.4% | 10–56 | 23.7 ± 14.3 | 29 ± 17.6 | 23.7 ± 14.7 |
Osteoblastoma | 53 | 4.4 | 28 | 2.3 | 25 | 2.1 | 52.8 vs 47.2% | 9–54 | 32.6 ± 10.5 | 26.5 ± 15.0 | 28.7 ± 13.2 |
Fibroma | 16 | 1.3 | 10 | 0.8 | 6 | 0.5 | 62.5 vs 37.5% | 26–76 | 41.6 ± 18.2 | 50.5 ± 15.0 | 44.9 ± 17.1 |
Osteoid osteoma | 17 | 1.4 | 8 | 0.7 | 9 | 0.7 | 47.1 vs 52.9% | 16–67 | 31.2 ± 22.3 | 39.0 ± 16.8 | 34.6 ± 19.8 |
Osteochondroma | 46 | 3.8 | 28 | 2.3 | 18 | 1.5 | 60.9 vs 39.1% | 13–64 | 34.0 ± 16.6 | 38.7 ± 20.8 | 36.1 ± 18.4 |
Solitary bone cyst | 25 | 2.1 | 8 | 0.7 | 17 | 1.4 | 32.0 vs 68.0% | 15–64 | 29.5 ± 15.2 | 48.8 ± 11.9 | 41.1 ± 16.2 |
Lipoma | 7 | 0.6 | 5 | 0.4 | 2 | 0.2 | 71.4 vs 28.6% | 23–63 | 41.8 ± 16.5 | 31.0 ± 11.3 | 38.7 ± 15.2 |
Aneurysmal bone cyst | 35 | 2.9 | 19 | 1.6 | 16 | 1.3 | 54.3 vs 45.7% | 10–62 | 25 ± 12.5 | 36.4 ± 15.3 | 30.4 ± 14.8 |
Fibrous dysplasia | 4 | 0.3 | 2 | 0.2 | 2 | 0.2 | 50.0 vs 50.0% | 25–32 | 29.5 ± 3.5 | 27 ± 2.8 | 28.3 ± 3.0 |
Malignant tumors | 429 | 35.5 | 286 | 23.7 | 143 | 11.8 | 66.7 vs 33.3% | 8–81 | 48.3 ± 16.7 | 46.3 ± 16.3 | 47.4 ± 16.5 |
PNET/ Ewing’s sarcoma | 17 | 1.4 | 9 | 0.7 | 8 | 0.7 | 52.9 vs 47.1% | 11–46 | 26 ± 13.3 | 25.8 ± 7.9 | 25.9 ± 10.9 |
Chordoma | 119 | 9.8 | 79 | 6.5 | 40 | 3.3 | 66.4 vs 33.6% | 27–81 | 56.6 ± 15.0 | 53.3 ± 13.3 | 55.5 ± 14.1 |
Malignant fibrous histiocytoma | 16 | 1.3 | 11 | 0.9 | 5 | 0.4 | 68.8 vs 31.2% | 29–67 | 51 ± 14.5 | 50.7 ± 1.9 | 50.9 ± 11.3 |
Liposarcoma | 1 | 0.0 | 1 | 0.0 | 0 | 0.0 | NA | 44 | 44 | NA | 44 |
Osteosarcoma | 13 | 1.1 | 5 | 0.4 | 8 | 0.7 | 38.5 vs 61.5% | 14–60 | 40.2 ± 21.0 | 25.8 ± 11.7 | 33.6 ± 18.2 |
Angiosarcoma | 10 | 0.8 | 7 | 0.6 | 3 | 0.2 | 70.0 vs 30.0% | 36–73 | 54.3 ± 11.3 | 45.0 ± 7.8 | 51.5 ± 10.9 |
Malignant neurilemmoma | 30 | 2.5 | 15 | 1.2 | 15 | 1.2 | 50.0 vs 50.0% | 8–71 | 40.4 ± 16.3 | 50.3 ± 12.1 | 45.3 ± 15.0 |
Plasma cell myeloma | 103 | 8.5 | 75 | 6.2 | 28 | 2.3 | 72.8 vs 27.2% | 10–76 | 49.8 ± 15.3 | 57.2 ± 12.6 | 52.0 ± 14.8 |
Malignant lymphoma | 54 | 4.5 | 30 | 2.5 | 24 | 2.0 | 55.6 vs 44.4% | 10–77 | 47.2 ± 21.0 | 46.5 ± 18.7 | 46.9 ± 19.6 |
Leiomyosarcoma | 1 | 0.0 | 1 | 0.0 | 0 | 0.0 | NA | 55 | 55 | NA | 55 |
Chondrosarcoma | 63 | 5.2 | 52 | 4.3 | 11 | 0.9 | 82.5 vs 17.5% | 20–68 | 46.1 ± 14.5 | 37.3 ± 14.8 | 44.0 ± 14.7 |
Fibrosarcoma | 2 | 0.2 | 1 | 0.0 | 1 | 0.0 | 50.0 vs 50.0% | 30–61 | 61 | 30 | 45.5 ± 21.9 |
Total | 1209 | 100 | 695 | 57.5 | 514 | 42.5 | 57.5 vs 42.5% | 8–81 | 39.1 ± 16.9 | 39.6 ± 16.7 | 39.3 ± 16.8 |